
    
      -  To select the optimal dose and dosing regimen of HM10560A for the subsequent phase III
           study on the basis of the safety and PK/PD profile after 24 weeks of treatment

        -  To assess the long term safety of HM10560A when administered in optimal dose range and
           dose frequency for additional 48 weeks (followed with 2 weeks safety follow up)
    
  